SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”) a teaching ...

SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology (termed “TC ...

SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd (“LongevityBank”) from ICH Capita ...

Core Insights - CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing affordable donor-derived cell-based immunotherapies for various cancers, including blood and solid tumors [1][3] - Executive Chairman Peter Choo has increased his shareholding in the company, now owning 21.95% of total outstanding shares, indicating his confidence in the company's potential [1][2] Company Overview - CytoMed was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [3] - The company specializes in proprietary technologies, including gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, aimed at creating novel allogeneic immunotherapies for cancer treatment [3] Market Context - There is rising investor interest in biotherapeutics in Asia, particularly in China, which presents unique opportunities for innovation and cost-competitive patient access [2] - The expanding healthcare and medical travel ecosystem in Southeast Asia, along with increasing healthcare costs in the West, further enhances the market potential for CytoMed's offerings [2]

Core Viewpoint - CytoMed Therapeutics Limited has submitted a cash bid for the acquisition of potentially synergistic assets from TC BioPharm Limited, aiming to enhance its expertise in allogeneic cell therapies for cancer treatment [1][3]. Group 1: Company Overview - CytoMed is a clinical stage biopharmaceutical company based in Singapore, focused on developing donor-derived cell-based immunotherapies for various cancers [1][6]. - The company was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [6]. Group 2: Proposed Acquisition - The proposed acquisition is intended to strengthen CytoMed's capabilities in using allogeneic cell therapies, accelerating its commercialization timeline and providing affordable treatment options for patients with unmet needs [3][4]. - This acquisition represents CytoMed's second acquisition in approximately one year, following the acquisition of a licensed cord blood bank in Malaysia [4]. Group 3: Clinical Development - Both CytoMed and TC BioPharm are engaged in the research and development of donor-derived allogeneic gamma delta T cells for cancer treatment, with TC BioPharm having completed a Phase I clinical trial and CytoMed conducting its Phase I ANGELICA Trial [2]. - CytoMed aims to leverage Southeast Asia's low-cost infrastructure to make cell therapies more accessible [4]. Group 4: Strategic Insights - The Chairman of CytoMed highlighted the potential of donor-derived gamma delta T cells for cancer treatment, referencing a recent publication from MD Anderson Cancer Center that supports this approach [4]. - The company is focused on developing cost-effective manufacturing processes for its therapies, particularly in light of recent developments in China to boost cell therapies [4].

Core Insights - The company reported a 100% increase in revenue to SGD 156,000 for the six months ended June 30, 2025 [2] - A net loss of $2.05 million was recorded, which could be reduced to $1.44 million when excluding certain costs [2] - Cash and bank balances stood at $2.86 million as of June 30, 2025, with a net tangible asset (NTA) of $7.15 million [2] Financial Performance Overview - Revenue for the first half of 2025 was generated from private banking services after acquiring the necessary license and assets [3] - Other operating income decreased by 8.5% year-on-year [2] - Loss per share was reported at $0.19 for the six months ended June 30, 2025 [2]

Financial Performance - Revenue increased by 100% to $156,000 for the six months ended June 30, 2025, compared to the same period in 2024 [3] - Other operating income decreased by 8.5% year on year, from $422,000 in H1 2024 to $386,000 in H1 2025 [5] - Net loss reported was $2,050,000 in 2025, which could be reduced to $1,440,000 when excluding certain costs [3][7] - Loss per share was $0.19 for the six months ended June 30, 2025 [4] - Cash and bank balances decreased from $4,970,000 as of December 31, 2024, to $2,860,000 as of June 30, 2025 [7] Business Line Performance - Revenue of $156,000 was generated from private banking services after acquiring a license and certain assets under IPSE depository in Malaysia [4] - Research expenses increased by 19.3% from $974,000 in H1 2024 to $1,160,000 in H1 2025, driven by higher employee benefits and clinical trial expenses [6] Market Data - The company reported a net loss in currency exchange of $402,000 and a net loss of $227,000 in fair value changes on warrant liability [5] - As of June 30, 2025, there were 72,371 warrants outstanding, with fair value changes of $76,000 recorded in the profit and loss account [8] Company Strategy and Industry Competition - The company is focusing on clinical trials and collaborations, with ongoing projects including CTM and iPSC GDNKT [9][10] - A new ATM agreement was signed with Levity to raise up to $4.3 million, indicating a strategy to enhance funding [11] - The corporate banking business is being rebranded as Longevity Bank, reflecting a strategic shift [11] Management Commentary on Operating Environment and Future Outlook - Management highlighted the completion of dose level one in a clinical trial and plans to complete Phase one trials in 2026 [9] - The company aims to apply for GDT trials in Malaysia and other locations, indicating a focus on expanding its market presence [10] Other Important Information - The company’s manufacturing facility has been audited by the Ministry of Health of Malaysia, ensuring compliance and operational readiness [11] Q&A Session Summary - The earnings call concluded without any questions from participants, indicating a lack of immediate inquiries regarding the financial performance or strategic direction [12]

Core Insights - CytoMed Therapeutics Limited has published a preclinical study indicating the potential of its allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML) [1][2] - The study was conducted in collaboration with The University of Texas, MD Anderson Cancer Center, under a research agreement established in May 2023 [1] - The findings support further clinical studies of allogeneic donor-derived γδ T cells for AML and other cancers, with plans to advance their next γδ T cell-based product into clinical trials [2] Company Overview - CytoMed, incorporated in 2018, is a clinical stage biopharmaceutical company focused on developing novel donor-derived cell-based immunotherapies for various cancers [3] - The company utilizes proprietary technologies, including gamma delta T cells and iPSC-derived gamma delta Natural Killer T cells, inspired by the success of CAR-T therapies in hematological malignancies [3] - CytoMed aims to provide innovative immunotherapy options for patients with limited treatment alternatives, particularly in Southeast Asia [3]

Revenue and Income - Revenue for the six months ended June 30, 2025, was S$155,887, compared to S$0 in the same period of 2024, indicating a significant increase[3] - Other operating income decreased to S$385,779 in 2025 from S$421,763 in 2024, reflecting a decline of approximately 8.5%[3] - Revenue from private blood storage services for the six months ended June 30, 2025, was S$130,280, while revenue from retrieval of private blood services was S$25,607, totaling S$155,887[22] Loss and Expenses - Total comprehensive loss for the period increased to S$2,269,263 in 2025 from S$1,083,150 in 2024, representing an increase of about 109%[3] - Loss before income tax for the six months ended June 30, 2025, was S$2,245,828, compared to S$1,088,543 in 2024, marking an increase of approximately 106%[3] - The loss per share attributable to equity holders of the Company was S$0.19 for the six months ended June 30, 2025, compared to S$0.09 in 2024[3] - The group reported a total loss of S$360,871 in June 30, 2024, which improved to a gain of S$272,848 in June 30, 2025, primarily due to fair value changes on warrant liabilities and currency exchange[27] - Research expenses increased from S$974,402 in June 30, 2024 to S$1,162,467 in June 30, 2025, with clinical trial expenses rising from S$239,805 to S$283,559[28] - Employee benefits expenses rose from S$646,640 in June 30, 2024 to S$809,704 in June 30, 2025, with total expenses after research classification increasing from S$299,167 to S$386,091[29] Assets and Liabilities - Total assets decreased to S$8,357,067 as of June 30, 2025, from S$10,067,749 as of December 31, 2024, a decline of about 17%[4] - Cash and bank balances decreased to S$2,854,958 as of June 30, 2025, from S$4,970,367 as of December 31, 2024, a reduction of approximately 43%[4] - Total liabilities increased to S$1,134,861 as of June 30, 2025, from S$1,023,960 as of December 31, 2024, an increase of about 11%[4] - The Group's total equity attributable to equity holders of the Company as of June 30, 2025, was S$7,146,525, down from S$10,162,106 as of June 30, 2024[7] - The Group's accumulated losses increased to S$17,091,895 as of June 30, 2025, from S$13,419,835 as of June 30, 2024[7] - Total borrowings increased from S$463,250 in December 31, 2024 to S$489,604 in June 30, 2025, with current borrowings rising from S$45,912 to S$57,835[50] Cash Flow - The company reported a net cash used in operating activities of S$1,599,164 for the six months ended June 30, 2025, compared to S$1,155,878 in 2024, indicating a worsening cash flow situation[5] - The Group's cash flow from operating activities was negative S$1,599,164 as of June 30, 2025, with working capital at S$3,380,056[17] - The Group had S$2,854,958 in cash and bank balances as of June 30, 2025, which is unrestricted for withdrawal and use[17] - Cash and cash equivalents decreased from S$4,697,047 in December 31, 2024 to S$2,854,958 in June 30, 2025, primarily due to a reduction in short-term fixed deposits[34] Shareholder Information - The weighted average number of ordinary shares used in computing basic and diluted loss remained relatively stable at approximately 11.54 million shares for both periods[3] - As of June 30, 2025, the total number of ordinary shares increased to 11,540,000, with a share capital amounting to S$23,793,950[51] - The company recognized share-based payments totaling S$448,327 for the period ending June 30, 2025, which includes S$86,941 in employee benefits expenses and S$361,386 in other expenses[54] Business Operations and Future Outlook - The Company completed the acquisition of the license and certain assets of Cellsafe International Sdn Bhd on August 15, 2024, expanding its market presence[12] - The Group's principal activities include research and development of immune cell and stem cell-based therapies, indicating a focus on innovation in the healthcare sector[11] - Management expects to recognize approximately S$335,000 in revenue from unsatisfied performance obligations in the next reporting period, with S$219,000 expected in the following year and S$23,000 beyond that[25] - The company operates in two business segments, focusing on immune cell-based immunotherapy and stem cell-based therapy[58] Commitments and Agreements - The company has a total capital commitment of S$137,234 as of June 30, 2025, with S$10,900 due within one year[60] - A loan commitment of S$500,000 is in place to establish a presence in China, with an interest rate of 5.0% per annum[61] - On July 1, 2025, the company issued 130,431 ordinary shares to professional service providers for approximately U.S.$309,121[63] - The company entered into an ATM Sales Agreement on August 18, 2025, allowing for the sale of ordinary shares up to an aggregate offering price of U.S.$4.30 million[64] Asset Management - The group acquired property, plant, and equipment worth approximately S$347,797 as of June 30, 2025, down from S$1,400,225 in December 31, 2024[35] - The total trade and other receivables increased from S$1,530,336 in December 31, 2024 to S$1,728,190 in June 30, 2025, with trade receivables rising from S$18,782 to S$24,705[33] - The total trade and other payables increased from S$441,023 in December 31, 2024 to S$477,690 in June 30, 2025, with trade payables rising from S$38,633 to S$82,735[44] - Non-current assets increased from S$3,846,096 on December 31, 2024, to S$4,063,570 on June 30, 2025, reflecting growth in asset value[56]

Core Insights - CytoMed Therapeutics Limited has successfully expanded clinical-scale natural killer (NK) cells from cord blood units that have been cryopreserved for over a decade, paving the way for new revenue streams and growth opportunities [1] - The company is reorganizing to create a new cord blood-derived biotech under LongevityBank Pte Ltd, which will focus on autologous therapies while CytoMed will concentrate on allogeneic therapies [2][3] - The acquisition of a licensed cord blood bank in Malaysia provides access to valuable cord blood for developing therapeutics for autoimmune diseases and cancers [4] Company Strategy - LongevityBank will leverage personalized cellular banking services for autologous therapies, while CytoMed will focus on donor blood-derived allogeneic therapies, which have ongoing clinical trials in Singapore and India [3] - The company plans to restart its cord blood banking business with new services, including immune cell banking, supported by resources from CytoMed [5] - Management intends to invest up to US$500,000 in LongevityBank to enhance laboratory capabilities and expedite research and development [5] Market Opportunity - The spinoff of LongevityBank is seen as a strategic move to manufacture cord blood-derived NK cells, which are being researched for their potential in treating autoimmune diseases [6] - The rising incidence of autoimmune diseases and increasing acceptance of personalized therapies present a favorable market environment for the company's offerings [7] - The cord blood bank acquisition is expected to positively impact the group's revenue, with better-than-anticipated performance [7]